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ABSTRACT
OBJECTIVE.Cytokines and other inflammatory mediators are involved in the patho-
genesis of otitis media. We hypothesized that polymorphisms in inflammatory
response genes contribute to the increased susceptibility to acute otitis media in
otitis-prone children.
PATIENTS AND METHODS.DNA samples from 348 children with 2 acute otitis media
episodes, who were participating in a randomized, controlled vaccination trial, and
463 healthy adult controls were included. Polymorphisms in TNFA, IL1B, IL4, IL6,
IL10, IL8, NOS2A, C1INH, PARP, TLR2, and TLR4 were genotyped. Genotype
distributions in children with recurrent acute otitis media were compared with
those in controls. Within the patient group, the number of acute otitis media
episodes before vaccination and the clinical and immunologic response to pneu-
mococcal conjugate vaccinations were analyzed.
RESULTS. The IL6-174 G/G genotype was overrepresented in children with acute
otitis media when compared with controls. In the patient group, TNFA promoter
genotypes 238 G/G and 376 G/G and the TLR4 299 A/A genotype were
associated with an otitis-prone condition. Furthermore, lower specific anticapsular
antibody production after complete vaccination was observed in patients with the
TNFA-238 G/G genotype or TNFA-863 A allele carriage. Finally, the IL10-1082
A/A genotype contributed to protection from the recurrence of acute otitis media
after pneumococcal vaccination.
CONCLUSIONS.Variation in innate immunoresponse genes such as TNFA-863A, TNFA-
376G, TNFA-238G, IL10-1082 A, and IL6-174G alleles in the promoter sequences
may result in altered cytokine production that leads to altered inflammatory
responses and, hence, contributes to an otitis-prone condition.
www.pediatrics.org/cgi/doi/10.1542/
peds.2007-0524
doi:10.1542/peds.2007-0524
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ACUTE OTITIS MEDIA (AOM) is the most commonbacterial infection in children. Overall, 10% to
15% of all children suffer from 4 AOM episodes per
year, which causes a great disease burden.1 Genetic poly-
morphisms in immunoresponse genes are known to in-
fluence susceptibility to and severity of infectious dis-
eases. For example, allelic variations in TNFA (tumor
necrosis factor A), IL1B (interleukin 1B), and IL6 have
been associated with meningococcal infection.2 Al-
though cytokines and other inflammatory mediators are
also involved in the pathogenesis of otitis media, the role
of polymorphisms in immunoresponse genes in recur-
rent AOM has been relatively unexplored thus far. In-
creased expression of TNF-, IL-1, IL-6, and IL-10 was
observed during experimental otitis media in animals.3,4
Therefore, in a common disease such as otitis media,
genetic variations may lead to altered inflammatory re-
sponses and an otitis-prone condition. For instance, bac-
terial endotoxin is recognized by several Toll-like recep-
tors (TLRs), which in turn stimulate TNF- production,
thus affecting numerous other pathways such as cyto-
kine production, immunoglobulin responses, and mucin
production.5–8 Remarkably, IL-1, IL-6, and TNF- levels
in nasopharyngeal secretions were found to be lower in
children with recurrent otitis media than in healthy
children.9
The influence of genetically determined variations on
otitis media can be illustrated by twin studies, which
have shown a heritability of 57% for acute ear infections
and 72% for chronic ear infections.10–14 Correlation for
recurrent otitis media is higher in monozygotic twins
(65%–71%) compared with dizygotic twins (25%–
34%).15 Streptococcus pneumoniae is an important patho-
gen in otitis media and is involved in at least 20% to
40% of all cases.16–18 Hence, genetic polymorphisms that
influence recurrence of otitis media may also be related
to response to pneumococcal antigens.
The effect of polymorphisms may result, for instance,
from altered expression levels or altered function caused
by amino acid substitutions. Variations in immunore-
sponse genes such as IL10, IL6, and IL4 have been asso-
ciated with altered cytokine expression levels.19–21 An
altered function caused by amino acid substitutions has
been reported for polymorphisms in TLR4 and poly-
(ADP-ribose) polymerase (PARP).22,23 The PARP 762A
variant was found recently to be associated with reduced
activity after H2O2 exposure, which is known to be
present in inflammation.23 Other polymorphisms were
selected in this study because of previous associations
with infectious or inflammatory diseases such as the IL8
C781T polymorphism, which was reported recently to be
associated with bronchiolitis caused by the respiratory
syncytial virus.24
In this study, we investigated whether polymor-
phisms in selected immunoresponse genes may contrib-
ute to the recurrence of otitis media and to clinical and
immunologic response to pneumococcal vaccination.
MATERIALS ANDMETHODS
Participants
Patients who initially participated in a randomized, con-
trolled study on prevention of recurrent AOM by pneu-
mococcal vaccinations were included.25 Children were
enrolled in the study after obtaining approval of the
medical ethical committee of the participating hospitals
and informed consent from the parents or guardians.
DNA was available from 348 white Dutch children, 1 to
7 years of age, who suffered from 2 AOM episodes in
the preceding year. The number of AOM episodes before
vaccination was based on both parental report (AOM
was defined as having 1 of these symptoms: acute
earache, new-onset otorrhea, irritability, and fever) and
clinical information of the diagnosis by a physician. Chil-
dren who did not have AOM episodes were not in-
cluded, because they were not likely to benefit from
vaccination. In the present study cohort, 122 children
suffered from 2 to 3 otitis media episodes, whereas 226
children suffered from 4 episodes (defined as an otitis-
prone condition) (Table 1).26 Children received either
pneumococcal vaccinations (n  168) or control vac-
cines (ie, hepatitis A [2 years or older] or hepatitis B
[younger than 2 years; n  180 vaccines]). In the pneu-
mococcal vaccine group, 1 dosage of 7-valent conjugate
vaccine (Prevnar; Wyeth, Rochester, NY) was adminis-
tered to children 2 to 7 years of age, whereas 2 dosages
were given with a 1-month interval to children of 1 to 2
years of age. In both groups, this procedure was followed
after 6 months by 1 dose of 23-valent polysaccharide
vaccine (Pneumune, Wyeth). Childrens’ progress was
followed until 18 months after completion of the vaccine
scheme to check for the recurrence of physician-diag-
nosed AOM.25
White Dutch adult controls (n  463) were derived
from the Dutch blood bank Sanquin after informed con-
sent was obtained and represented healthy adult donors.
No records of previous history regarding AOM were
available for these adult controls; however, in the gen-
eral population, 3.2 AOM episodes is expected in
childhood.26 Children aged 0 to 13 years had an esti-
mated number of 120 episodes of physician-diagnosed
AOM per 1000 person-years in the Netherlands in the
period 1995–2003.27 This infers that controls will have
experienced, on average, fewer AOM episodes per year
than the patients.
Experimental Procedures
Genotyping
Single base extension analysis was used to genotype
inducible nitric oxide synthase (NOS2A) S608L (refer-
ence single-nucleotide polymorphism [rs] 2297518),
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PARP V762A (rs1136410), complement component in-
hibitor-1 (C1INH), V480M (rs4926), IL4 C-524T
(rs2243250), IL10 G-1082A (rs1800896), IL10 C-819T
(rs3021097), IL1B C-31T (rs1143627), TNFA A-863C
(rs1800630), TNFA T-857C (rs1799724), TNFA G-376A
(rs3093659), TNFA G-308A (rs1800629), TNFA G-238A
(rs361525), IL6 G-174C (rs1800795), IL8 C781T
(rs2227306), TLR4 D299G (rs4986790), and TLR4 T399I
(rs4986791) (www.ncbi.nlm.nih.gov/SNP). In short, the
genomic region of interest was amplified by using poly-
merase chain reaction. After purification, a single base
extension was performed by using a primer ending 1
nucleotide before the single-nucleotide polymorphism
(SNP) location. Up to 7 SNPs were analyzed in 1 multi-
plex assay. A poly-T tail attached to the primer combined
with the use of a Liz size marker served to distinguish
SNPs in the multiplex analysis (Tables 2 and 3). The
TLR2 R753Q polymorphism (rs5743708) was deter-
mined by using Taqman analysis with primers TLR2-
753F CCATTCCCCAGCGCTTCT and TLR2-753R CCAG-
GTAGGTCTTGGTGTTCATT and probes TLR2-753V1
VIC-AAGCTGCAGAAGAT and TLR2-753M1 FAM-AA-
GCTGCGGAAGAT. A subset of polymerase chain reac-
tion samples was sequenced to confirm genotypes. All
genotypes were annotated independently by 2 investi-
gators who were blinded to the clinical data.
Antibody Measurements
In children with 2 AOM episodes, a blood sample was
taken for immunologic assessment before and 1 month
TABLE 1 Characteristics of Patients With>2 AOM Episodes
Characteristics 2–3 Episodes of AOM (N 122) 4 Episodes of AOM (N 226) Pa
Male gender, n (%) 84 (69) 128 (57) .03
Age, median (minimum–maximum), y 2.42 (1.0–6.3) 2.10 (1.0–7.0) .40
Age group (12–48 mo), n (%) 84 (69) 180 (80) .03
Age at ﬁrst AOM, geometric mean (SD), mo 10.1 (2.0) 7.7 (2.1) .001
Breastfeeding for3 mo, n (%) 57 (47) 96 (43) .50
Tobacco smoke exposure indoors, n (%) 41 (34) 70 (31) .63
Day care
At age 12–24 mo, n/N (%) 22/44 (50) 42/99 (42) .47
At age 25–48 mo, n/N (%) 70/78 (90) 113/127 (89) 1.00
No. of siblings .02
Median (minimum–maximum) 1.0 (0–3) 1.0 (0–7)
Mean 0.93 1.17
Family history of AOM
Parents (121 of 225), n (%) 79 (65) 131 (58) .21
Siblings, n/N (%) 48/86 (56) 98/182 (54) .79
Atopy, n (%)b 54 (44) 117 (52) .22
a Fisher’s exact test, Mann-Whitney U test, and t test were performed when appropriate.
b Atopy was deﬁned as having eczema, hay fever, or recurrent wheezing or asthma.
TABLE 2 Polymerase Chain Reaction Primer Sequences
Pool No. Upper 533 Lower 533 rs No. Change
Pool 1
NOS2A GCAGGGCTAGGAGTAGGA AGCCCCATATGTAAACCAA 2297518 608 S/L
PARP CTGCCCCTGTTCTACCA ACTGTAGGCCACCTCGAT 1136410 762V/A
Pool 2
C1INH CCTCCGCCATCTCTGT GCTCGCCCTAACCTGA 4926 480 V/M
IL4 CTTGCCAAGGGCTTCCTTAT TGGAAACTGTCCTGTCATGG 243250 C-524T
Pool 3
IL10 TCCCCTTACCTTCTACACAC GACCCCTACCGTCTCTATTT 1800896 G-1082A
IL1B CTTGCCCTTCCATGAAC TGCCTCGAAGAGGTTTG 1143627 C-31T
TNFA.1 CCCCTCCCAGTTCTAGTT GGGACACACAAGCATCA 361525 G-238A
1800629 G-308A
3093659 G-376A
TNFA.2 GGAGAATGTCCAGGGCTATG AAAATCAGGGACCCCAGAGT 1800630 A-863C
1799724 T-857C
Pool 4
TLR4 ATGCCCCTACTCAATCTCTCT GCCAGCCATTTTCAAGACT 4986790 299 D/G
4986791 399 T/I
IL6 TTGTCAAGACATGCCAAGTGCT GCCTCAGAGACATCTCCAGTCC 1800795 G-174C
IL8 AGCTTGCCTACTATAAATAACA CTAGCCCTTGACCTCAG 2227306 C781T
Pool 5
IL10 TCCCCTTACCTTCTACACAC GACCCCTACCGTCTCTATTT 3021097 C-819T
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after complete vaccination. Prevaccination and postvac-
cination immunoglobulin G (IgG) levels to the 7 pneu-
mococcal serotypes included in the conjugate vaccine
were measured in serum by enzyme-linked immunosor-
bent assay as described previously.28,29
Statistical Analysis
Statistical analysis was performed by using SPSS 11.0
(SPSS Inc, Chicago, IL) and Stata 8 (Stata Corp, College
Station, TX). Verification of Hardy-Weinberg equilib-
rium of genotypes was performed by using the 2 test (1
degree of freedom). Binomial variables were analyzed by
using Pearson’s 2 test (2 degrees of freedom) or Fisher’s
exact test when appropriate. Continuous variables were
compared for the different genotypes by using the
Mann-Whitney U test. When necessary, variables were
log-transformed to obtain an approximately normal dis-
tribution.
A comparison of genotype frequencies was made be-
tween patients and the reference control group. In ad-
dition, genotype frequencies in children who suffered
from 2 to 3 episodes per year were compared with those
of patients who had 4 episodes after correction for
gender, number of siblings, age, log-transformed age at
the time of the first AOM episode, and the interaction
term between the latter 2 by using binary logistic regres-
sion. Log-transformed age at the first AOM episode was
included in the analysis, because an early first infection
predisposes to a second AOM episode. A child who has
had a first AOM episode at a younger age has had a
longer period of time to develop multiple AOM episodes
than a child of the same age who suffered from the first
infection at a later age. Because the interaction between
the age at the first AOM episode and the age of inclusion
was significant, it was accounted for in the analyses.
Log-transformed antibody levels were compared be-
tween individuals with different genotypes. Age, num-
ber of AOM episodes (2–3 vs 4), and the number of
conjugate vaccinations (1 or 2) were included in the
analyses that assessed the effect of the different geno-
types. Only when genotypes were consistently associ-
ated with different serotype-specific antibodies was this
association considered relevant.
To determine the involvement of SNPs on the occur-
rence of AOM after complete vaccination, negative bi-
nomial regression was used, because it allows for extra
variation (overdispersion). The time of follow-up was
measured from 1 month after complete vaccination to
the end of the study. Effects were corrected for treat-
ment (antipneumococcal vaccinations or hepatitis vacci-
nations) and the number of AOM episodes in the year
preceding vaccinations (2–3 vs 4). P values of .05
were considered to be statistically significant. No correc-
tion was made for multiple testing.
RESULTS
We investigated the association between variations in
the genes listed in Table 2 and the occurrence of 2
episodes of AOM, the number of AOM episodes before
vaccination, specific antipneumococcal IgG levels after
vaccination, and AOM after complete vaccination, re-
spectively. Only significant associations will be dis-
cussed. SNPs not mentioned here showed no significant
associations.
Genotype distribution for all SNPs except for the IL10
G-819A polymorphism reached Hardy-Weinberg equi-
TABLE 3 Primer Sequences for Single Base Extension Reactions
Pool No. Primer Sequence 53 3 Primer Length,
Bases
Pool 1
PrNOS2AU TTTTGCTCTTTCAGCATGAAGAGC 24
PrPARPL TTTTTTTTTTGCAGGTTGTCAAGCATTTCC 30
Pool 2
PrIL4U TAAACTTGGGAGAACATTGT 20
PrC1INHU TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGCAGCAGCCCTTCCTCTTC 66
Pool 3
PrTNFA2863U AGTCGAGTATGTGGACCCCC 20
PrIL101082L TTTTTTTTTTTTACCTATCCCTACTTCCCC 30
PrTNFA1238U TTTTTTTTTTTTTTTTTTTTTTAGAAGACCCCCCTCGGAATC 42
PrIL1BL TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCTCCCTCGCTGTTTTTAT 48
PrTNFA1308L TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCTAGAGGCTGAACCCCGTCC 54
PrTNFA1376U TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGCCTGCATCCTGTCTGGAA 66
PrTNFA2857L TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCTCTACATGGCCCTGTCTTC 72
Pool 4
PrIL6L AATGTGACGTCCTTTAGCAT 24
PrIL8L TTTTTTTTTTCATAACTGACAACATTGAAC 30
PrTLR4299U TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCTTAGACTACTACCTCGATG 60
PrTLR4399L TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGATCTAAATACTTTAGGCTG 72
Pool 5
PrIL10819U TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCCCTTGTACAGGTGATGTAA 82
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librium in controls. To rule out technical problems, 14
individuals were typed by using the reverse and forward
primer in the single base extension reaction. Results for
both strands were identical. Sequencing of 13 random
controls also showed identical genotypes, excluding
technical errors (data not shown). Genotype distribu-
tions in controls are listed in Table 4.
IL6-174 G/G Genotype Is AssociatedWith Susceptibility to
AOM
The number of children with the IL6-174 C/C, IL6-174
C/G, and IL6-174 G/G genotypes in the total cohort of
patients with AOMwas 49 (14.1%), 156 (45%), and 142
(40.9%), respectively. The corresponding frequencies in
controls were 82 (17.8%), 232 (50.4%), and 146
(31.7%), respectively. The IL6-174 G/G genotype was
found more frequently in patients with AOM (1014)
compared with controls than the C/G genotype (odds
ratio [OR]: 1.45; P .02) or the C/C genotype (OR: 1.64;
P  .02).
TNFA Promoter Genotypes238 G/G and376 G/G and TLR4
299 D/D Genotype Are AssociatedWith an Otitis-Prone
Condition
Similar to other otitis studies, in our study, population
risk factors for AOM such as a high number of siblings
and low age at first AOM are related to an otitis-prone
condition (Table 1).13,30,31 Girls were overrepresented in
the group of children who suffered from 4 AOM epi-
sodes when compared with the children who had 2 to 3
AOM episodes. Children under the age of 4 were more
likely to have had4 AOM episodes in the previous year
than older children. The interaction of age and age at the
first AOM episode was significantly associated with the
AOM recurrence rate (P  .01). Therefore, the effect of
the polymorphisms on the recurrence rate of AOM was
corrected for these factors (Table 5).
The TNFA-238 G/G genotype was overrepresented in
the otitis-prone children compared with the children
with 2 to 3 AOM episodes (crude OR: 2.13; P  .03;
adjusted OR: 2.29; P  .03). Because a difference was
observed in the recurrence-rate distribution in children
over and under the age of 4 years, these data were also
analyzed separately. The association was mainly attrib-
utable to children under the age of 4 years.
The TNFA-376 G/G genotype was associated with the
otitis-prone condition in children (crude OR: 3.10; P 
.05; adjusted OR: 3.06; P  .07). No significant associa-
tion was found when older and younger children were
analyzed separately.
In addition, carriage of the TLR4 299 G allele was
associated with a lower number of AOM episodes (OR:
0.5; P  .04). This finding, however, remained signifi-
cant only after correction for confounding factors when
the data for the children under the age of 4 years were
TABLE 4 Genotype Distribution of Polymorphisms in White Dutch
Controls
SNP Genotype Frequency, n (%)
NOS2a 608
G/G 302 (65.2)
G/A 140 (30.2)
A/A 21 (4.5)
PARP 762
T/T 300 (66.7)
T/C 140 (31.1)
C/C 10 (2.2)
C1INH 480
G/G 256 (55.5)
G/A 176 (38.2)
A/A 29 (6.3)
TNF-863
C/C 330 (71.4)
C/A 117 (25.3)
A/A 15 (3.2)
TNF-857
C/C 387 (84.5)
C/T 66 (14.4)
T/T 5 (1.1)
TNF-376
G/G 447 (96.8)
G/A 15 (3.2)
A/A —
TNF-308
G/G 301 (65.2)
G/A 147 (31.8)
A/A 14 (3.0)
TNF-238
G/G 415 (89.8)
G/A 47 (10.2)
A/A —
IL4–524
C/C 340 (73.8)
C/T 112 (24.3)
T/T 9 (2.0)
IL1B-31
C/C 57 (12.5)
C/T 215 (47)
T/T 185 (40.5)
Il10–1082
G/G 123 (26.7)
G/A 219 (47.6)
A/A 118 (25.7)
IL10–819
C/C 284 (61.6)
C/T 145 (31.5)
T/T 32 (6.9)
IL6–174
C/C 82 (17.8)
C/G 232 (50.4)
G/G 146 (31.7)
IL8 781
C/C 152 (32.8)
C/T 235 (50.8)
T/T 76 (16.4)
TLR4 299
A/A 374 (86.4)
A/G 58 (13.4)
G/G 1 (0.2)
TLR4 399
C/C 379 (87.1)
C/T 54 (12.4)
T/T 2 (0.5)
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analyzed separately (crude OR: 2.50; P  .02; adjusted
OR: 2.49; P  .03).
TNFA-863 C/C Genotype and Carriage of the TNFA-238 A Allele
Are AssociatedWith Higher Speciﬁc Antipneumococcal IgG
Levels After Complete Vaccination
IgG antipneumococcal antibody levels were evaluated in
80 children who were in the pneumococcal vaccine
group: 34 were aged 12 to 24 months and 46 were aged
25 to 84 months. Four or more AOM episodes in the
year preceding inclusion were observed in 36 children,
whereas 44 had 2 to 3 episodes of AOM. Before vacci-
nation, all IgG antipneumococcal antibody levels were
low for patients with 2 to 3 and4 AOM episodes (Table
6). Serum IgG antipneumococcal antibody levels against
all serotypes were lower in the children with an AOM
recurrence rate 4 compared with those with only 2 to
3 AOM episodes after complete vaccination. This was
significant for all except the anti–serotype 6B and 23F
antibody levels. Age, independent from the number of
AOM episodes (2–3 or 4), had a significant effect on
specific IgG levels against serotype 14 at baseline, and on
anti–serotype 4 antibody levels after vaccination. By us-
ing a logistic regression model adjusting for age, number
of AOM episodes, and number of conjugate vaccina-
tions, a significantly lower antipneumococcal serotype
23F antibody level was observed for the carriers of the
TNFA-863 A allele compared with children homozygous
for the C allele (P  .001). Furthermore, a trend for
lower specific IgG levels was observed against 5 of 7
TABLE 5 Genotype Distribution of TNFA and TLR4 Polymorphisms in ChildrenWith AOM
SNP Controls, n
(%)
2–3 Episodes of AOM,
n (%)
4 Episodes of AOM,
n (%)
2–3 vs4
Crude OR (P) Adjusted
OR (P)a
All patients G/G vs G/A
TNFA G-238A 462 120 222
G/G 415 (89.8) 101 (84.2) 204 (91.9) 2.13 (.03) 2.29 (.03)
G/A 47 (10.2) 19 (15.8) 18 (8.1) — —
A/A 0 (0.0) 0 (0.0) 0 (0.0) — —
Patients4 y
G/G — 68 (82.9) 162 (92.0) 2.38 (.03) 3.06 (.01)
G/A — 14 (17.1) 14 (8.0) — —
A/A — 0 (0.0) 0 (0.0) — —
Patients4 y
G/G — 33 (86.8) 42 (92.3) 1.59 (.51) 1.41 (.66)
G/A — 5 (13.2) 4 (8.7) — —
A/A — 0 (0.0) 0 (0.0) — —
All patients G/G vs G/A and A/A
TNFA G-376A 462 120 222
G/G 447 (96.8) 112 (93.3) 217 (97.7) 3.10 (.05) 3.06 (.07)
G/A 15 (3.2) 8 (6.7) 4 (1.8) — —
A/A 0 (0.0) 0 (0.0) 1 (0.5) — —
Patients4 y
G/G — 77 (93.9) 172 (97.7) 2.79 (.13) 3.05 (.12)
G/A — 5 (6.1) 3 (1.7) — —
A/A — 0 (0.0) 1 (0.6) — —
Patients4 y
G/G — 35 (92.1) 45 (97.8) 3.85 (.25) 2.74 (.44)
G/A — 3 (7.9) 1 (2.2) — —
A/A — 0 (0.0) 0 (0.0) — —
All patients D/D vs D/G and G/G
TLR4 299, D/G 433 121 216
D/D 374 (86.4) 99 (81.8) 194 (89.8) 1.96 (.04) 1.66 (.14)
D/G 58 (13.4) 20 (16.5) 22 (10.2) — —
G/G 1 (0.2) 2 (1.7) 0 (0.0) — —
Patients4 y
D/D — 67 (80.7) 157 (91.3) 2.50 (.02) 2.49 (.03)
D/G — 14 (16.9) 15 (8.7) — —
G/G — 2 (2.4) 0 (0.0) — —
Patients4 y
D/D — 32 (84.2) 37 (84.1) 0.99 (.99) 0.65 (.54)
D/G — 6 (15.8) 7 (15.9) — —
G/G — 0 (0.0) 0 (0.0) — —
Data are from the crude and adjusted logistic regression analysis.
a Adjusted OR indicates the effect of SNP adjusted for gender, number of siblings, age, log (age at ﬁrst AOM episode), and the interaction of the latter 2.
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vaccine serotypes (P  .05–.10) in the carriers of the
863A allele. The TNFA-238 A allele carriers had higher
geometric mean specific IgG levels against all serotypes
(Table 7). This finding, however, was only significant for
antibodies against pneumococcal serotypes 18C and 19F
without correction for confounding factors (P  .04 and
.04, respectively).
No significant differences in specific IgG levels were
observed for the IL6-174 G/C and the IL10-1082 G/A
and IL10-819 C/T genotypes (data not shown).
IL10-1082 A/A Genotype Is AssociatedWith Protection From
AOM Recurrence After Vaccination
Previously, we have reported that the number of AOM
episodes in the per-protocol analysis was higher in the
pneumococcal vaccine group than in the control vaccine
group, particularly among children who suffered 4
AOM episodes in the year preceding inclusion.25 We
corrected for this feature to assess whether the polymor-
phisms were correlated to the number of AOM episodes
after complete vaccination. Patient characteristics did
not differ between the pneumococcal and control vac-
cine group.25 We observed that the IL10-1082 A/A ge-
notype protects patients from AOM recurrence during
follow-up after vaccination (incidence rate ratio: 0.63; P
 .01).
No significant differences were observed for polymor-
phisms in TNFA or IL6 (data not shown).
DISCUSSION
In this study, we found an association between TNFA
promoter polymorphisms and otitis-prone condition and
specific IgG production after pneumococcal vaccination.
The TNFA-238 G/G genotype was associated with the
otitis-prone condition and a trend for lower specific anti-
pneumococcal antibody levels after vaccinations com-
pared with carriers of the A allele. The TNFA-863 A allele
was also associated with a trend for lower specific anti-
pneumococcal IgG levels compared with children with
the TNFA-863 C/C genotype. The TNFA-376 G/G geno-
type was also associated with an otitis-prone condition.
Similar to Joki-Ekkila et al32, we found no association
between the TNFA-308 promoter polymorphism and re-
current AOM. In a recent study, an association was
reported between carriage of the rare TNFA-308 allele
and susceptibility to AOM. The allele frequencies of the
TNFA-308 polymorphism, however, differed from what
is usually reported for this polymorphism.33 Differences
in the observed associations between the TNFA pro-
moter polymorphisms may, indeed, result from differ-
ences in allele frequency in the population and the effect
of haplotypes. This finding may be specifically true for
rare polymorphisms such as the TNFA-376 G/A poly-
morphism. For our study, however, the limited number
of patients prohibited haplotype analysis.
TNF- levels in nasopharyngeal secretions are de-
creased in children with recurrent otitis media compared
with healthy children.9 TNF- stimulates Ig and mucin
production, and low TNF- concentrations may compro-
mise these defense mechanisms.7 The association be-
tween various TNFA polymorphisms and otitis media
parameters found in our study may indicate that, in-
deed, there is a role for these polymorphisms in TNF-
production in vivo. In the recent past, numerous studies
have been performed to investigate the association of
TNFA promoter polymorphisms and TNF- levels in dif-
ferent inflammatory and infectious diseases, and contra-
dictory results have been reported34. TNF- expression is
probably not determined by one polymorphism but,
rather, by a combination of polymorphisms in TNFA and
TNFA-associated genes. Different pathogens may induce
a variety of cytokine responses and, because numerous
pathogens, both bacterial and viral, are known to cause
otitis media, unraveling the role of polymorphisms on
TNF- production in the human setting is very difficult.
Because TNF- levels are expected to change during the
course of infection, the timing of sampling is likely to be
a very important determinant of the results.
In addition, the IL6-174 G/G promoter genotype was
found more frequently in patients with AOM than in
healthy adult controls in our study. Our findings support
the findings of others (eg, the study by Nieters et al35)
TABLE 6 Geometric Mean (95% Conﬁdence Interval) of Speciﬁc Antipneumococcal IgG in ChildrenWith
2 to 3 AOM Episodes and ChildrenWith>4 AOM Episodes Before Vaccination and 1 Month
After Complete Vaccination
Total IgG Against
Capsular Type
Before Vaccination Pa 1 mo After Complete Vaccination Pa
2–3 AOM Episodes
(n 36)
4 AOM Episodes
(n 44)
2–3 AOM Episodes
(n 36)
4 AOM Episodes
(n 44)
4 0.05 (0.04–0.07) 0.05 (0.04–0.06) .61 5.91 (4.6–7.6) 3.55 (2.6–4.8) .01
6B 0.04 (0.03–0.05) 0.04 (0.04–0.05) .74 1.39 (0.7–2.7) 0.75 (0.4–1.4) .20
9V 0.22 (0.16–0.31) 0.18 (0.13–0.25) .37 43.48 (31–61) 20.18 (14–30) .01
14 2.20 (1.27–3.82) 1.17 (0.84–1.61) .05 117.84 (85–164) 59.94 (47–77) .001
18C 0.27 (0.18–2.50) 0.20 (0,14–0.28) .29 12.80 (9.9–17) 7.79 (6.0–10) .01
19F 0.43 (0.26–0.71) 0.23 (0.18–0.30) .02 25.81 (18–36) 8.16 (5–12) .001
23F 0.53 (0.40–0.71) 0.57 (0.43–0.75) .65 4.91 (3.6–6.7) 3.28 (2.3–4.8) .12
a P values were corrected for age by using regression analysis.
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who found homozygosity of the IL6-174C allele to be
associated with a lower frequency of reported common
colds. Common colds are known to predispose for recur-
rent otitis media. In addition, Patel et al33 reported IL6-
174 G allele carriage to be increased in otitis-media-
susceptible children. The IL6 G/G genotype was shown
previously to be associated with high IL-6 levels com-
pared with the C/C genotype21. This association, how-
ever, is not consistent, and a more complex regulation of
IL-6 production that depends on multiple polymor-
phisms in the IL6 promoter region seems to play a
role.36,37 Furthermore, IL-6 expression is influenced by
TNF-, and the interaction of polymorphisms in these
and other genes may codetermine the phenotype.
Carriage of the TLR4 299 G allele was associated with
a lower number of AOM episodes but was significant
only in children younger than 4 years after corrections
for confounding factors. Possibly, a low G allele fre-
quency in our population (10% in the group with 2–3
AOM episodes versus 5% in the otitis-prone group)
hampered identification of an association. TLRs recog-
nize microbial patterns in a specific way. It is thought
that, depending on the microorganism involved, a com-
bination of TLRs is triggered, which determines the di-
rection of the immune response.38 Detailed information
on the causative pathogens in each disease episode is
needed to elucidate the precise role of TLRs and their
genetic variation in AOM and other diseases. Unfortu-
nately, these data are not available in our study.
The IL10-1082 A/A genotype was associated with
protection from AOM after vaccination. The IL10 pro-
moter haplotype, which includes the IL10-1082 A/A
genotype, is associated with low IL-10 production.19,39,40
For the IL10-819 C/C genotype, which is in the same
haplotype, a similar trend was observed (data not
shown). In IL-10-deficient mice immunized with non-
virulent unencapsulated Streptococcus pneumoniae (strain
R36A), elevated induction of proinflammatory cytokines
was observed, which supports the hypothesis that low
IL-10 producers confer better response after vaccination.
Antibody titers against pneumococcal proteins were in-
creased compared with those in wild-type mice.41 Al-
though no association was observed between the IL10
polymorphism and specific antibody levels in our popu-
lation, one might expect a similar effect. Possibly, the
concentration of IL-10 in low producers is sufficient to
preclude finding differences in antibody titers.
Because otitis media is a multifactorial disease, the
effect of each polymorphism on its own is expected to be
limited. In addition, we are aware that most of these
associations are expected to lose significance after cor-
rection for multiple testing. However, because no con-
sensus has been reached on what method to use to
correct for multiple testing in genetic-association studies,
we felt it most appropriate to provide P values as they
are.
The associations in our study were attributable
mainly to children younger than 4 years. Several factors
may explain this finding. First, a selection for children
suffering from 2 episodes of otitis media for the vacci-
nation trial may have resulted in a biased group in the
older children, including those children with the highest
recurrence rates or ongoing infection. Second, the im-
mune system and anatomy, like the Eustachian tube, of
young children are both still developing and differ from
older children and adults, which likely results in a more
prominent role for innate immunity at younger age. In
contrast to previous studies, our study only included
patients with recurrent AOM and no age-matched con-
trols without otitis were included.30,42
CONCLUSIONS
We have shown that several polymorphic variants in
immunoresponse genes (ie, IL6-174 G/C, TNFA-863
TABLE 7 Geometric Mean (95% Conﬁdence Interval) of Speciﬁc Antipneumococcal Antibodies 1 Month After Complete Vaccination for
Different TNFA-863 and TNFA-238 Genotypes
SNP IgG Against Pneumococcal Capsular Type
4 6B 9V 14 18C 19F 23F
TNFA-863
C/C
(n 54)
5.00 (3.9–6.4) 1.27 (0.8–2.1) 33.29 (24–45) 90.11 (69–118) 10.12 (8.0–13) 16.00 (11–23) 5.22 (4.0–6.8)
C/A and A/A
(n 26)
3.52 (2.3–5.3) 0.60 (0.3–1.4) 20.66 (12–36) 65.52 (47–92) 8.99 (6.4–13) 9.93 (6.0–17) 2.19 (1.4–3.5)
P (crude) .12 .10 .10 .16 .80 .13 .001
P (adjusted)a .05 .10 .06 .10 .42 .05 .001
TNFA-238
G/G (n 66) 4.53 (3.7–5.5) 0.93 (0.6–1.5) 27.36 (21–36) 76.22 (61–95) 8.87 (7.4–11) 11.86 (8.6–16) 3.74 (2.9–4.9)
G/A (n 12) 4.17 (1.6–11) 1.89 (0.5–6.7) 34.88 (9.7–125) 125.04 (61–257) 15.54 (6.9–35) 27.83 (12–67) 5.03 (2.1–12)
P (crude) .78 .23 .54 .10 .04 .04 .41
P (adjusted)a .70 .46 .77 .21 .06 .07 .39
Data are from the crude and adjusted logistic regression analysis.
a P (adjusted) indicates the effect of SNP adjusted for age, AOM rate (2–3 vs4), and number of conjugate vaccinations (1 or 2).
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A/C, TNF-376 G/A, TNFA-238 G/A, TLR4 D/G, and
IL10-1082 G/A) are suggested to have a potential influ-
ence on middle-ear infections. Because the various ge-
notypes are expected to interact with each other and
numerous environmental and host factors, additional
functional and genetic studies are warranted to elucidate
their individual contributions to the recurrence of AOM.
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PEOPLE IN ETHNICALLY DIVERSE SETTINGS DON’T CARE ABOUT EACH OTHER
“Diversity was once just another word. Now it’s a fighting word. One of the
biggest problems with diversity is that it won’t let you alone. Corporations
everywhere have force-marched middle managers into training sessions led
by ‘diversity trainers.’ Most people already knew that the basic idea beneath
diversity emerged about 2000 years ago under two rubrics: Love thy neighbor
as thyself, and Do unto others as they would do unto you. Then suddenly this
got rewritten as ‘appreciating differentness.’ George Bernard Shaw is said to
have demurred from the Golden Rule. ‘Do not do unto others as you would
have them do unto you,’ Shaw advised. ‘Their tastes may not be the same.’
No such voluntary opt-out is permissible in our time. The parsons of the press
made diversity into a secular commandment; do a word-search of ‘diversity’
in a broad database of newspapers and it might come up 250 million times. In
the Supreme Court term just ended, the Seattle schools integration case led
most of the justices into arcane discussions of diversity’s legal compulsions.
More recently it emerged that the University of Michigan, a virtual mecca of
diversity, announced it would install Muslim footbaths in bathrooms, causing
a fight. Now comes word that diversity as an ideology may be dead, or not
worth saving. Robert Putnam, the Harvard don who in the controversial
best-seller Bowling Alone announced the decline of communal-mindedness
amid the rise of home-alone coach potatoes, has completed a mammoth
study of the effects of ethnic diversity on communities. His researchers did
30 000 interviews in 41 US communities. Short version: People in ethnically
diverse settings don’t want to have much of anything to do with each other.
‘Social capital’ erodes. Diversity has a downside. Prof Putnam isn’t exactly
hiding these volatile conclusions. . . . He wasn’t happy with what he found
but didn’t mince words describing the results: ‘Inhabitants of diverse com-
munities tend to withdraw from collective life, to distrust their neighbors,
regardless of the color of their skin, to withdraw even from close friends, to
expect the worst from their community and its leaders, to volunteer less, give
less to charity and work on community projects less often, to register to vote
less, to agitate for social reformmore, but have less faith that they can actually
make a difference, and to huddle unhappily in front of the television.’ The
diversity nightmare gets worse: They have little confidence in the ‘local news
media.’ This after all we’ve done for them.”
Henninger D.Wall Street Journal. August 16, 2007
Noted by JFL, MD
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